Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Repare Therapeutics Inc
(NQ:
RPTX
)
3.010
+0.040 (+1.35%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Repare Therapeutics Inc
< Previous
1
2
3
Next >
Repare Therapeutics Provides Corporate Update and Highlights Key Milestones Anticipated in 2022
January 07, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Expands Executive Leadership Team with the Appointment of Philip Herman as EVP Commercial & New Product Development
January 05, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors
December 21, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Insiders Establish New and Modified Automatic Securities Disposition Plans
December 15, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
November 15, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
November 10, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Announces Closing of Upsized Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
November 02, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Announces Pricing of Upsized Offering of Common Shares
October 27, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Announces Proposed Public Offering of Common Shares
October 27, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Participate at the H.C. Wainwright 2nd Annual Precision Oncology Conference
October 18, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Presents Preliminary Phase 1 Monotherapy Clinical Data from the Ongoing First-in-Human Phase 1/2 TRESR Study of RP-3500 in Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 08, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Issues Statement Regarding Inadvertent Issuance of Phase 1/2 TRESR RP-3500 Clinical Trial Abstract by the AACR-NCI-EORTC Virtual International Conference
October 07, 2021
From
Repare Therapeutics, Inc.
Via
Business Wire
Repare Therapeutics to Present Initial Data from the Phase 1/2 TRESR RP-3500 Clinical Trial at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
September 30, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Appoints Thomas Civik to Its Board and as New Chairman
September 07, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Participate at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference
September 02, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
August 12, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Participate at the 42nd Annual Goldman Sachs Virtual Global Healthcare Conference
June 02, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
May 13, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1
May 03, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Present at the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference
April 13, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Highlight Program Progress for RP-6306 at Today’s Virtual Investor Day Event
April 08, 2021
From
Repare Therapeutics Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.